Video Guide

Catalyst Database

Chronological list of catalyst events. Click "See Drug Details" to view detailed info in our AmpCard. Use the Sort options or search box below (e.g. "Phase 2") to filter the catalyst results.

Sort Table By:

Ticker

Catalyst Date

Reset Search

Ticker

Drug | Disease (links)

Stage (next event)

Catalyst Date

BDTX

Phase 2

BDTX-1535

Non-small cell lung cancer (NSCLC) (1L), Non-classical EGFRm NSCLC

Q2 2025

1L NSCLC (Non-classical EGFRm NSCLC). Presentation at AACR '24. 5/9/24- Enrollment ongoing. 3/6/25- Clinical data on track for Q2 2025.

Data readout

ARCT

Phase 2

ARCT-032

Cystic Fibrosis (CF) Lung Disease, Ornithine Transcarbamylase (OTC) Deficiency

Q2 2025

LUNAR CF trial: 11/27/23- Granted Orphan Drug Designation. 6/7/24 Positive interim Ph1b data at CF conference. 9/3/24- IND cleared to initiate a Ph2 MAD. 1/6/25- Initiated dosing in Ph2 MAD. 3/6/25- Interim data in Q2 2025.

Data readout

ABUS

Phase 1a/b

AB-101

cHBV (Hepatitis B virus)

H1 2025

AB-101-001 trial. 9/12/23- 1st patient dosed . 5/2/24- Moved into Part 2 which evaluates MAD in healthy subjects. 11/6/24- Moved into Part 3 of trial with preliminary data in H1 2025.

Data Readout

ARMP

Phase 2a

AP-SA02

Bacteremia (Staphylococcus aureus)

H1 2025

diSArm study. Completed 1st cohort dosing & initiated dosing in 2nd cohort in Q1 2023. 3/21/24- Complete trial in 2024. 3/20/25- Topline data in H1 2025.

Data readout

KRON

Phase 1/2

Istisociclib/KB-0742 (CDK9 Inhibitor)

Amplified Solid Tumors

H1 2025

3/5/24- Present poster at AACR '24 on April 8th. 4/25/24- Clinical update at ASCO '24. 7/23/24- First patient dosed in expansion cohort and provide efficacy update in H1 2025. 9/23/24 New preclinical data at AACR.

Data readout

CGEM

Phase 1

CLN-619 (MICA/B) +/- pembrolizumab

Solid tumors

H1 2025

03/01/24- Received IND clearance. Updated clinical data in Q2 2024. Initial data from disease-specific dose expansion cohorts in H1 2025. 4/24/24- Present clinical data at ASCO '24 on June 1, 2024 & investor call.

Data readout

ACIU

Phase 2

ACI-7104.056

Early Parkinson's Disease (PD)

H1 2025

VacSYn study. 1/3/24- Completed enrollment of cohort 1 and commenced cohort 2. 11/14/24- Interim data reported. 3/13/25- Further interim data in H1 2025 w/ initiation of Part 2 in H2 2025.

Data readout

CRBU

Phase 1

CB-011

Relapsed or Refractory Multiple Myeloma

H1 2025

CaMMouflage trial. 3/29/23- First patient dosed. Enrollment ongoing in dose level 3. 3/10/25- Dose escalation data in H1 2025.

Data readout

ALT

Phase 2b

Pemvidutide (ALT-801) (GLP-1R/GCGR)

Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Q2 2025

IMPACT trial. 6/5/24- Data at EASL 2024 on 5th-8th June. 6/22/24 Presents at ADA '24. 8/8/24- Enrollment progressing. 9/30/24- Completed enrollment; topline data in Q2 2025. Presentation of Ph1b 12-week at AASLD '24 on 11/15. 11/15/24- New data on inflammatory lipids in subjects w/ MASLD at AASLD '24. 2/27/25- Topline results in Q2 2025.

Data readout

VRTX

Phase 1

VX-522

Cystic fibrosis (CF)

H1 2025

Collab w/Moderna: 2/5/24- Completed dosing SAD, initiated MAD portion and dosing patient. 2/10/25- MAD potion underway w/ data in H1 2025.

Data readout

Amp Volatility is calculated based off of options pricing with expiration after event.
Last Calculated: 03/13/20